This filing is a routine PDMR equity grant disclosure with no trading implications. Monitor the next quarterly earnings release for any operational or financial updates that could affect the stock.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 2 $28.66entry
- T+1 · 3mo ago +0.10%α −0.94% · $28.69
- T+5 · 2mo ago −3.63%α −2.67% · $27.62
- T+20 · 7w ago −7.26%α −7.10% · $26.58
- T+52 · todayOpen
- T+60 · in 10d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Smith & Nephew filed a routine 6-K disclosing equity awards to Nate Folkert, President of Orthopaedics, under the company's Performance Share Plan 2026 and Restricted Share Plan 2024. The awards are standard long-term incentive compensation with multi-year vesting and performance conditions, representing no material change to the company's financial outlook or operations. This filing is administrative in nature and carries no actionable trading signal.
Key Facts
- Nate Folkert, President of Orthopaedics, received a performance share award of 117,933 shares under the Performance Share Plan 2026, vesting on 15 March 2029 subject to performance conditions.
- Nate Folkert also received a restricted share award of 67,164 shares under the Restricted Share Plan 2024, vesting in equal annual tranches over three years.
- Both awards were granted on 1 September 2026 at a market price of £11.0265 per share.
- The awards are standard long-term incentive compensation for a PDMR and do not involve any open-market purchase or sale of shares.
Financial Impact
No material financial impact. The awards represent standard equity compensation with no immediate cash outlay or dilution beyond existing plan limits.
Risk Factors
- No material risks identified from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (SNN), Batch item 1 | 0001654954-26-008086 |
| Document: 0001654954-26-008086-index-headers.html | 0001654954-26-008086 |
| Document: 0001654954-26-008086-index.html | 0001654954-26-008086 |
| Document: 0001654954-26-008086.txt | 0001654954-26-008086 |
| 6-K Filing (SNN), Batch item 5 | 0001654954-26-008086 |
| Document: 0001654954-26-008086-index-headers.html | 0001654954-26-008086 |
| Document: 0001654954-26-008086-index.html | 0001654954-26-008086 |
| Document: 0001654954-26-008086.txt | 0001654954-26-008086 |
Track record
42 reports on SNN
6 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +8.02% at T+20 after the Jun 30, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 12, 20264d ago 6-K Neutral 1/10 Entry $31.00 Now $30.97 −0.10% settles Nov 19
- Nov 4, 202612d ago 6-K Bearish 6/10 No price data
- Nov 4, 202612d ago 6-K Bearish 6/10 Entry $32.46 to $31.04 Now $30.97 +4.59% ▲ +4.37% +3.46% vs SPY
- Nov 2, 202614d ago 6-K Neutral 4/10 Entry $30.24 to $31.05 Now $30.97 +2.41% ▲ +2.68% +2.60% vs SPY
- Oct 22, 202625d ago 6-K Neutral 2/10 Entry $30.88 to $30.22 Now $30.97 +0.29% ▼ −2.14% −2.84% vs SPY
- Oct 8, 20265w ago 6-K Neutral 2/10 Entry $26.96 to $29.09 Now $30.97 +14.87% ▲ +7.90% +8.18% vs SPY
- Oct 1, 20266w ago 6-K Neutral 2/10 Entry $26.58 to $26.96 Now $30.97 +16.52% ▲ +1.43% +0.13% vs SPY
- Oct 1, 20266w ago 6-K Neutral 2/10 Entry $26.58 to $26.96 Now $30.97 +16.52% ▲ +1.43% +0.13% vs SPY
- Sep 23, 20267w ago Press Release Neutral 3/10 Entry $26.82 to $26.96 Now $30.97 +15.47% ▲ +0.52% +1.20% vs SPY
- Sep 23, 20267w ago Press Release Neutral 3/10 Entry $26.82 to $26.96 Now $30.97 +15.47% ▲ +0.52% +1.20% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers